UNITED STATES OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. [_______])*
ANTEX BIOLOGICS INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.01 PER SHARE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
03672W100
- --------------------------------------------------------------------------------
(CUSIP number)
MARCH 13, 2000
--------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/ / Rule 13d-1(b)
/ x / Rule 13d-1(c)
/ / Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 4
<PAGE>
SCHEDULE 13G
CUSIP No. 03672W100 Page 2 of 4 Pages
________________________________________________________________________________
NAME OF REPORTING PERSON
CHL Medical Partners, L.P.
1 S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
06-149-0934
________________________________________________________________________________
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
2 (b) [_]
________________________________________________________________________________
SEC USE ONLY
3
________________________________________________________________________________
CITIZENSHIP OR PLACE OF ORGANIZATION
4
Delaware, United States
________________________________________________________________________________
SOLE VOTING POWER
5
NUMBER OF 3,030,202 (1)
SHARES _________________________________________________________________
SHARED VOTING POWER
BENEFICIALLY 6
OWNED BY
_________________________________________________________________
EACH SOLE DISPOSITIVE POWER
7
REPORTING 3,030,202 (2)
PERSON _________________________________________________________________
SHARED DISPOSITIVE POWER
WITH 8
________________________________________________________________________________
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORT PERSON
9
3,030,202
________________________________________________________________________________
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
________________________________________________________________________________
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
6.1%
________________________________________________________________________________
TYPE OF REPORTING PERSON*
12
PN
________________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
ITEM 1.
(a) NAME OF ISSUER:
Antex Biologics Inc.
(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICE:
300 Professional Drive
Gaithersburg, Maryland 20879
ITEM 2.
(a) NAME OF PERSON FILING:
CHL Medical Partners, L.P.
(b) ADDRESS OF PRINCIPAL BUSINESS OFFICES:
1055 Washington Boulevard
Stamford, Connecticut 06901
(c) CITIZENSHIP:
Delaware, United States
(d) TITLE OF CLASS OF SECURITIES:
Common Stock, par value $.01 per share
(e) CUSIP NUMBER:
03672W100
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B),
CHECK WHETHER THE PERSON FILING IS a:
Not applicable
ITEM 4. OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED:
3,030,202
(b) PERCENT OF CLASS:
6.1%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 3,030,202
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of:
3,030,202
(iv) Shared power to dispose or to direct the disposition of:
0
Page 3 of 4
<PAGE>
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
Not applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
Not applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
Not applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
Not applicable
ITEM 9. NOTICE OF DISSOLUTION OF THE GROUP:
Not applicable
ITEM 10. CERTIFICATION:
By signing below, I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing control of the issuer of the
securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
CHL MEDICAL PARTNERS, L.P.
By: COLLINSON HOWE & LENNOX, LLC
Its General Partner
March 23, 2000 /s/ Timothy F. Howe
__________________________ By:____________________________________
Date Name: Timothy F. Howe
Title: Manager
Page 4 of 4
<PAGE>
